Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia

Amin, Alpesh; Ortendahl, Jesse; Harmon, Amanda L; Kamat, Siddhesh; Stellhorn, Robert; Chase, Sandra L.; Sundar, Shirin V.

doi:10.1093/ajhp/zxy064

Cited by 5 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method of estimating costs was not explicitly stated in the majority of studies (58/87; 67%) (ESM 3). Based on the reviewers’ interpretation, 41 studies employed a bottom-up approach (cost profile is constructed using disaggregated patient-level data), seven used a top-down approach [ 47 , 64 , 65 , 71 , 74 , 76 , 90 ] (total expenditure divided by number of patients treated), and one study [ 25 ] used a mixed costing method. Information reported by the remaining studies ( n = 38, only published as abstracts) did not allow for conclusions to be drawn on the costing approach.…”

Section: Resultsmentioning

confidence: 99%

“…The cost estimates for each comorbidity-related subgroup are presented in ESM 5. The age subgroup analyses showed that the cost of hospitalization was 5–31% higher for patients with HF aged < 65 years than those aged ≥ 65 years [ 62 , 63 , 65 , 67 , 74 , 92 ].…”

Section: Resultsmentioning

confidence: 99%

“…The perspective of the economic analysis was adequately reported and justified in 19 studies (44%); less than half (21/43; 40%) [ 22 , 24 , 25 , 44 , 46 , 47 , 49 , 53 , 59 , 60 , 63 , 65 , 67 – 69 , 74 , 81 , 87 – 89 , 116 ] did not clearly define the perspective but the available information allowed for interpretation in line with published definitions [ 117 ]; three studies (10%), only published as abstracts, left the perspective completely undefined [ 34 , 90 , 97 ].…”

Section: Resultsmentioning

confidence: 99%

“…Only five studies estimated the costs for a HF event for a period greater than 1 year [ 44 , 46 , 71 , 75 , 88 ], and only one of them discounted costs incurred after the first year. Time horizon was not applicable for the remaining five economic model studies, from which only de-novo cost inputs were extracted [ 45 , 53 – 55 , 74 ]. In all the studies, the answer to the study question was given, conclusions followed from the data reported, and in all but six studies (14%, only published as abstracts) [ 34 , 49 , 73 , 86 , 90 , 97 ] the conclusions were accompanied by the appropriate caveats.…”

Section: Resultsmentioning

confidence: 99%

“…For example, depending on the specific comorbidity, HF hospitalization costs varied by nearly five-fold [ 58 , 60 ] and total medical costs over 1 year by nearly four-fold [ 73 , 89 ]. Surprisingly, younger patients (aged < 65 years) were associated with higher costs than older patients (aged ≥ 65 years); the cost increase range was 5–31% [ 62 , 63 , 65 , 67 , 74 , 92 ]. The lower costs among the older patients may reflect a higher rate of mortality, which affects both the number of admissions and the length of hospital stay of older patients.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)

et al. 2020

View full text Add to dashboard Cite

Background Heart failure presents a growing clinical and economic burden in the USA. Robust cost data on the burden of illness are critical to inform economic evaluations of new therapeutic interventions. Objectives This systematic literature review of heart failure-related costs in the USA aimed to assess the quality of the published evidence and provide a narrative synthesis of current data. Methods Four electronic databases (MEDLINE, EMBASE, EconLit, and the Centre for Reviews and Dissemination York Database, including the NHS Economic Evaluation Database and Health Technology Assessment Database) were searched for journal articles published between January 2014 and March 2020. The review, registered with PROSPERO (CRD42019134201), was restricted to cost-of-illness studies in adults with heart failure events in the USA. Results Eighty-seven studies were included, 41 of which allowed a comparison of cost estimates across studies. The annual median total medical costs for heart failure care were estimated at $24,383 per patient, with heart failure-specific hospitalizations driving costs (median $15,879 per patient). Analyses of subgroups revealed that heart failure-related costs are highly sensitive to individual patient characteristics (such as the presence of comorbidities and age) with large variations even within a subgroup. Additionally, differences in study design and a lack of standardized reporting limited the ability to compare cost estimates. The finding that costs are higher for patients with heart failure with reduced ejection fraction compared with patients with preserved ejection fraction highlights the need for differentiating among different heart failure types. Conclusions The review underpins the conclusion drawn in earlier reviews, namely that hospitalization costs are the key driver of heart failure-related costs. Analyses of subgroups provide a clearer understanding of sources of heterogeneity in cost data. While current cost estimates provide useful indications of economic burden, understanding the nuances of the data is critical to support its application. Electronic supplementary material The online version of this article (10.1007/s40273-020-00952-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)

et al. 2020

View full text Add to dashboard Cite

show abstract

Water – A life-giving toxin – A nephrological oxymoron. Health consequences of water and sodium balance disorders. A review article

Mitrosz-Gołębiewska

Rydzewska–Rosołowska

Kakareko

et al. 2022

Advances in Medical Sciences

View full text Add to dashboard Cite

Global burden of heart failure: a comprehensive and updated review of epidemiology

Savarese

Becher

Lund

et al. 2022

Cardiovascular Research

1,014

500

View full text Add to dashboard Cite

Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by significant morbidity and mortality, poor functional capacity and quality of life, and high costs. HF affects more than 64 million people worldwide. Therefore, attempts to decrease its social and economic burden have become a major global public health priority. While the incidence of HF has stabilized and seems to be declining in industrialized countries, the prevalence is increasing due to the aging of the population, improved treatment of and survival with ischemic heart disease, and the availability of effective evidence-based therapies prolonging life in patients with HF. There are geographical variations in HF epidemiology. There is substantial lack of data from developing countries, where HF exhibits different features compared with that observed in the Western world. In this review, we provide a contemporary overview on the global burden of HF, providing updated estimates on prevalence, incidence, outcomes, and costs worldwide.

show abstract

Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia

Cited by 5 publications

References 20 publications

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)

Water – A life-giving toxin – A nephrological oxymoron. Health consequences of water and sodium balance disorders. A review article

Global burden of heart failure: a comprehensive and updated review of epidemiology

Contact Info

Product

Resources

About